O-GlcNAc transferase (OGT) inhibitor with in vitro and in vivo efficay.
ST045849 (TT04) is an O-GlcNAc transferase (OGT) Inhibitor (IC50/human splice variant = 30 μM/sOGT & 53 μM/ncOGT; 6.25 μM UDP-GlcNAc, 500 μM peptide substrate KKKYPGGSTPVSSANMM). ST045849 is typically employed in the 1-100 μM range for probing O-GlcNAcylation-dependent cellular processes in cultures, although low 10-50 nM and high 1-20 mM dosing ranges have also been reported. Daily oral administration is reported to prevent embryos neural tube defects at E10.5 among diabetic pregnant mice (20 mg/kg/day p.o. from E6.5 to E9.5).
We hypothesized that a disproportionate activation of the glucosamine (GlcN) pathway, caused by a prolonged exposure to hyperglycaemia, could impair endothelial integrity promoting endoplasmic reticulum (ER) stress. We also tested the possibility that SRT1720 may be able to counteract GlcN-induced
Resistance to insulin action is a key cause of diabetic complications, yet much remains unknown about the molecular mechanisms that contribute to the defect. Glucose-induced insulin resistance in peripheral tissues such as the retina is mediated in part by the
Journal of the American Chemical Society, 127(42), 14588-14589 (2005-10-20)
O-GlcNAcylation of serine and threonine residues is a dynamic and essential post-translational modification involved in signaling pathways in eukaryotes. Studies of O-GlcNAcylation would be aided by small-molecule inhibitors of O-GlcNAc transferase (OGT), the sole enzyme know to mediate this modification
Rab3A is a small Ras-like GTPase critical for membrane traffic. Although the functions of Rab3A have been reported in several cancers, the roles of Rab3A in hepatocellular carcinoma (HCC) have never been determined. To investigate the potential roles of Rab3A
Biochemical and biophysical research communications, 478(4), 1497-1502 (2016-08-18)
GNB2L1 is an intercellular scaffold protein of the Trp-Asp (WD) repeat protein family, and has been reported to play suppressive roles in the progression of gastric cancer. However, the regulatory mechanisms of GNB2L1 in gastric cancer still remain largely elusive.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
